Video

Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

Author(s):

Aref Al-Kali, MD

In Partnership With:

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Related Videos
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Nicolas Girard, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Related Content
Cheryl L. Willman, MD
October 3rd 2024

Mayo Clinic to expand access to state-of-the-art cancer care through transformational gift

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Saad J. Kenderian, MB, ChB
September 30th 2024

Using a Molecular Scissors to Improve CAR T-Cell Therapy

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sikander Ailawadhi, MD
September 25th 2024

As Blood Cancer Treatments Evolve, So Does The Patient Journey

Richard Vile, PhD, Mayo Clinic
September 18th 2024

Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works